Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial

In patients with metastatic breast cancer, taxane treatment demonstrates activity but is not curative. Targeted treatment modalities are therefore necessary in order to improve outcomes in this group. A randomized placebo-controlled phase II trial was initiated to evaluate effect and toxicity of gef...

Descripción completa

Detalles Bibliográficos
Autores principales: Engebraaten, Olav, Edvardsen, Hege, Løkkevik, Erik, Naume, Bjørn, Kristensen, Vessela, Ottestad, Lars, Natarajan, Vasanti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scholarly Research Network 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361199/
https://www.ncbi.nlm.nih.gov/pubmed/22666610
http://dx.doi.org/10.5402/2012/176789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361199/
https://www.ncbi.nlm.nih.gov/pubmed/22666610
http://dx.doi.org/10.5402/2012/176789

Ejemplares similares